We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Novo Nordisk A/S (NOVO-B.KO) expects its closely-watched diabetes treatment Victoza to reach European customers in the nearest future, Chief Scientific Officer Mads Krogsgaard Thomsen said in an ...

Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.KO) said Wednesday its drug Victoza has been shown in a clinical study to be more efficient than a competing drug in improving diabetes ...

A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

The research is based on a review of electronic health records on more than 125,000 adults who began taking GLP-1 drugs – liraglutide ... active ingredient in Novo Nordisk's weight loss drug ...